Welcome to our dedicated page for Apimeds Pharmaceuticals US SEC filings (Ticker: APUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apimeds Pharmaceuticals US, Inc. filings document a Delaware clinical-stage biopharmaceutical issuer with common stock registered on NYSE American under APUS and emerging growth company status. Recent 8-K and 12b-25 records cover material definitive agreements, governance and executive changes, shareholder written-consent and voting matters, preferred stock and convertible-note conversion disclosures, and capital-structure matters.
The filing record also includes notices tied to delayed Form 10-K reporting and NYSE American continued-listing compliance, along with disclosures related to settlement agreements and merger-related governance matters. Periodic and event filings frame Apimeds' operating and financial results, risk factors, and clinical or regulatory disclosures for the Apitox program.
Apimeds Pharmaceuticals US, Inc. is implementing a 1-for-10 reverse stock split of its issued and outstanding common stock. Stockholders holding a majority of the voting power approved the action by written consent on December 1, 2025.
The company plans to file a charter amendment in Delaware on or about March 25, 2026, and has set 12:01 a.m. Eastern Time on March 26, 2026 as the effective time. Apimeds expects its common stock to begin trading on a split-adjusted basis on the NYSE American under the symbol APUS on March 26, 2026, with a new CUSIP of 03771D201.
Apimeds Pharmaceuticals US, Inc. is notifying stockholders that consenting holders holding approximately 51% approved several corporate actions on December 1, 2025, including conversions of Series A preferred and convertible notes, a proposed 1-for-10 reverse stock split (board may elect to implement or abandon), an amendment to reduce par value from $0.01 to $0.001, an increase of shares available under the 2024 Equity Incentive Plan to 2,096,679, and adoption of a 2025 Equity Incentive Plan.
The approvals were taken in connection with a merger that closed on December 1, 2025, after which MindWave became a direct wholly owned subsidiary and MindWave holders, on an as-converted, fully diluted basis, will collectively hold 90.9% of the Company’s equity. The Preferred Stock Conversion and Notes Conversion will not be effected unless NYSE American approves the Company’s new listing application. The Information Statement was first mailed on or about March 5, 2026 and the actions become effective on or about March 25, 2026 (at least twenty calendar days after mailing).
Apimeds Pharmaceuticals US, Inc. filed Amendment No. 2 to its Form 8-K to add financial disclosures related to a previously reported reverse merger. The amendment supplies unaudited consolidated financial statements as of September 30, 2025, audited statements for the years ended March 31, 2025 and 2024, and unaudited pro forma consolidated financial information required by Item 9.01. It does not report new events after the original 8-K and does not change earlier disclosures except for providing these financial exhibits.
Apimeds Pharmaceuticals US, Inc. filed Amendment No. 2 to its current report to add full financial statements and unaudited pro forma information for its reverse merger with MindWave Innovations Inc. MindWave is a digital-asset-focused business holding $132.3 million of digital assets at fair value as of September 30, 2025, mainly Bitcoin, Tether and its native NILA token.
MindWave reported net income of $55.9 million for the year ended March 31, 2025, driven by unrealized and realized gains on digital assets, and a net loss of $6.6 million for the six months ended September 30, 2025 as digital asset values moved the other way. The pro forma data treat MindWave as the accounting acquirer, with its prior shareholders holding 90.9% of Apimeds’ equity on an as-converted basis at closing, highlighting that the combined company is effectively MindWave’s public listing vehicle.
Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri report a 9.99% beneficial stake in Apimeds Pharmaceuticals US, Inc. They collectively beneficially own 1,397,021 shares of common stock issuable upon conversion of certain convertible notes, subject to a 9.99% ownership blocker, as of December 31, 2025.
The reported percentage is based on 12,575,983 Apimeds common shares outstanding as of November 12, 2025, plus 1,397,021 shares issuable from the notes. Each reporting person has sole voting and dispositive power over the 1,397,021 shares and certifies a passive, ordinary-course investment intent.
Apimeds Pharmaceuticals US, Inc. has completed a reverse merger with MindWave Innovations Inc., making MindWave a wholly owned subsidiary and giving former MindWave stockholders, on an as-converted and fully diluted basis, 90.9% of the company’s equity through a mix of common and preferred stock.
Certain majority stockholders have already approved by written consent several key actions: conversion of Series A preferred stock into common shares, conversion of sizable senior convertible notes issued under a Securities Purchase Agreement, a potential 1-for-10 reverse stock split with a par value reduction from $0.01 to $0.001, an increase in the 2024 equity plan to 2,096,679 issuable shares, and adoption of a new 2025 equity plan. The board may still choose whether or not to implement the reverse split.
The company also describes a senior convertible note financing of up to $120,900,000 at an 8% original issue discount, with an initial tranche made available at closing and additional funding tied to effectiveness of a resale registration statement and investor elections. Existing common stockholders keep their current shares but will sit alongside a new controlling stockholder base and significant convertible securities once the actions become effective.
Apimeds Pharmaceuticals US, Inc. reported a change in its board of directors. On December 30, 2025, stockholders acting by written consent removed Erik Emerson from the company’s board, effective the same day. The action was approved by stockholders holding a majority of the outstanding common stock voting power entitled to vote in director elections, in line with the company’s organizational documents and applicable law. The filing states that other individuals remain on the board of directors, though they are not named here.
Apimeds Pharmaceuticals US, Inc. reported that on December 5, 2025, two members of its Board of Directors resigned. Director Dr. Vin Menon and Independent Director Amir A. Dossal both stepped down from their board positions.
The company stated that these resignations were not due to any disagreement regarding its operations, policies, or practices. Dr. Menon continues to serve as Chief Executive Officer, as he signed the report in that capacity. The filing focuses solely on this board-level leadership change and does not include financial results or transaction details.
Apimeds Pharmaceuticals US, Inc. filed an amended current report to correct drafting mistakes in its previously disclosed MindWave Innovations merger and related preferred stock designation. The Merger Agreement is revised to remove provisions that had incorrectly given MindWave the right to appoint directors, to set the Common Stock Cap at 0% of Apimeds common shares, and to state that Series A preferred stock issued to existing MindWave holders will represent 90.9% of Apimeds’ fully diluted equity. The company also corrects its Certificate of Designation so that 7,477,017 shares of Series A Convertible Preferred Stock are designated, instead of 7,263,865. In addition, Apimeds discloses Amendment No. 1 to a Securities Purchase Agreement covering up to $120,900,000 of senior convertible notes, clarifying variable-rate transaction restrictions, expanding investor notification rights for other funding events, and extending the deadline for the Initial Closing.